ONO-4007, an Antitumor Lipid A Analog, Induces Tumor Necrosis Factor-α Production by Human Monocytes Only under Primed State: Different Effects of ONO-4007 and Lipopolysaccharide on Cytokine Production

  1. Norihito Matsumoto,
  2. Yoshiya Aze,
  3. Akira Akimoto and
  4. Tsuneo Fujita
  1. Fukui Research Institute, Ono Pharmaceutical Co., Ltd., Fukui, Japan
     
    Next Section

    Abstract

    ONO-4007 is a synthetic lipid A analog that exhibits strong antitumor activity in several animal models via intratumoral production of tumor necrosis factor (TNF). In the present study, the cytokine-inducing effect of ONO-4007 was investigated in human monocytes that were freshly isolated or had been incubated for 3 days with granulocyte-macrophage colony-stimulating factor (GM-CSF) or macrophage colony-stimulating factor. ONO-4007 induced slight production of TNF-α, Interleukin (IL)-1β, IL-6 and IL-12 in fresh monocytes but strongly induced TNF-α production in GM-CSF-treated monocytes. Monocytes treated with macrophage colony-stimulating factor were also primed to produce TNF-α in response to ONO-4007. In the production of IL-1β, IL-6 and IL-12, GM-CSF did not show a priming effect. In contrast to ONO-4007, lipopolysaccharide (LPS) induced significant amounts of all these cytokines in fresh monocytes. In whole blood, ONO-4007 failed to induce TNF-α, whereas LPS and LA-15-PP (Escherichia coli-type lipid A) strongly induced TNF-α production. In the GM-CSF-treated monocytes, both elimination of serum from the culture medium and anti-CD14 antibody treatment attenuated LPS-induced TNF-α production but not ONO-4007-induced TNF-α production. This study shows that ONO-4007 activates human monocytes/macrophages to release TNF-α only in a primed state and suggests that ONO-4007 would activate these cells viadifferent pathways from LPS. These differences could mean that ONO-4007 has potent antitumor activity with lower toxicity than LPS.

    LPS is a component of the cell wall of Gram-negative bacteria that exhibits a variety of biological activities, including both toxicity and immunopotentiating activity (Homma et al., 1985; Kanegasakiet al., 1986). The lipid moiety, lipid A, is an active part of LPS. Lipid A and its analogs exhibit various immunopharmacological activities, i.e., activation of macrophages (Matsuuraet al., 1995), immunoadjuvant activity (Takada et al., 1985; Ulrich and Myers, 1995), B cell mitogenicity (Kotaniet al., 1983), induction of resistance to bacterial infection (Schutze et al., 1994) and antitumor activity (Nakatsuka et al., 1989). ONO-4007, sodium 2-deoxy-2-[3S-(9-phenylnonanoyloxy)tetradecanoyl]-amino-3-O-(9-phenylnonanoyl)-d-glucopyranose 4-sulfate (fig. 1), is a monosaccharide lipid A analog with low toxicity. ONO-4007 exhibits strong antitumor activity via intratumoral TNF production and induces macrophages to a tumorcidal state in MM46 mammary carcinoma-bearing mice (Yang et al., 1994). ONO-4007 also induces high levels of TNF within tumor tissue in KDH-8 hepatoma-bearing rats (Kuramitsu et al., 1997), and intratumoral injection of anti-TNF-α antibody attenuates the antitumor activity of ONO-4007 (N. Matsumoto and A. Akimoto, unpublished observation). These findings suggest that the antitumor effect of ONO-4007 is mediated by endogenous TNF-α production from tumor-infiltrating macrophages. TNF-inducing activity of ONO-4007 in human monocytes/macrophages, however, has not been examined.

    Figure 1
    View larger version:
    Figure 1

    Chemical structure of ONO-4007.

    Several analogs of lipid A have been shown to display species-specific pharmacological activities. For example, GLA-60, a monosaccharide lipid A analog, activates both human monocytes (Maeda et al.,1990) and murine macrophages (Matsuura et al., 1995), whereas lipid IVA, a disaccharide precursor of lipid A, inhibits LPS-induced activation of human monocytes although it activates murine macrophages (Golenbock et al., 1991; Deludeet al., 1995), and Rhodobacter sphaeroides lipid A inhibits LPS-induced activation of both human monocytes and murine macrophages (Golenbock et al., 1991; Delude et al., 1995). In contrast to its effects in mice and rats, ONO-4007 has little or no ability to induce TNF production when injected into cynomolgus monkeys, dogs or rabbits (N. Matsumoto and A. Akimoto, unpublished observation), which suggests that the pharmacological features of ONO-4007 are species-specific.

    GM-CSF and M-CSF enhance the survival (Erickson-Miller et al., 1990) and differentiation (Geissler et al., 1989;Dimri et al., 1994; Hashimoto et al., 1997) of cultured human monocytes. Moreover, pretreatment of human monocytes with GM-CSF (Cannistra et al., 1988) or M-CSF (Sampson-Johannes and Carlino, 1988; Asakura et al., 1996) enhances TNF-α production in response to subsequent LPS stimulation, a result that indicates functional priming activity of GM-CSF and M-CSF on human monocytes.

    In this study, to elucidate cytokine-inducing activity of ONO-4007 in human monocytes/macrophages, we used freshly isolated human monocytes and monocytes functionally primed by incubation with GM-CSF or M-CSF and investigated the induction of cytokines (TNF-α, IL-1β, IL-6 and IL-12) in response to ONO-4007. In comparison with ONO-4007, LPS derived from Salmonella abortus equi was used as a reference agent, because clinical trials in cancer patients have been reported (Engelhardt et al., 1991 and 1995).

    Previous SectionNext Section

    Materials and Methods

    Materials.

    ONO-4007, synthesized at Ono Pharmaceutical Co., Ltd (Osaka, Japan), was dissolved in dimethyl sulfoxide and further diluted with culture medium for monocyte activation or added to whole blood (final dimethyl sulfoxide concentration, 0.1% and 0.5%, respectively). LPS from Salmonella abortus equi was obtained from Sigma (St. Louis, MO), LA-15-PP (Escherichia coli-type synthetic lipid A) from Daiichi Pure Chemicals (Tokyo, Japan), rhGM-CSF (2.05 × 108 U/mg) from Genzyme (Cambridge, MA), rhM-CSF (6.5 × 107 U/mg) from Cellular Products (Buffalo, NY) and monoclonal anti-CD14 (RMO52) from Cosmo Bio (Tokyo, Japan). The culture medium consisted of RPMI-1640 (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 0.3 g/l glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% FCS (Gibco-BRL, Grand Island, NY).

    Monocyte separation.

    Peripheral blood mononuclear cells were obtained from heparinized venous blood of healthy adults by density centrifugation with Lymphocyte Separation Medium (Organon Teknika, Durham, NC). Mononuclear cells suspended in culture medium were incubated in autologous serum-coated dishes at 37°C for 60 min. Then nonadherent cells were removed by three washes with prewarmed culture medium, and adherent cells were collected by treatment with 1 mM EDTA. The adherent cells were found to be ≥93% monocytes by Wright stain.

    Cell culture.

    All cell cultures were performed at 37°C in 5% CO2/95% air and 100% humidity. Monocytes, freshly isolated or preincubated for 3 days in the presence of GM-CSF or M-CSF in 24-well culture plates, were washed and stimulated with ONO-4007 or LPS for 3, 6 or 24 h. Heparinized whole blood of healthy adults was stimulated with ONO-4007, LA-15-PP or LPS for 6 h. Supernatants were obtained by centrifugation and stored below −20°C until measurement of cytokines. To assess the requirement of serum in TNF-α production, we compared the effect of FCS-free medium with the effect of culture medium containing 10% FCS when GM-CSF-treated monocytes were stimulated with ONO-4007 or LPS. To assess the effect of anti-CD14 on TNF-α production in GM-CSF-treated monocytes, we added anti-CD14 antibody (10 μg/ml) to cultures 15 min before stimulation.

    Cytokine determination by ELISA.

    Concentrations of TNF-α, IL-1β, IL-6 and IL-12 (p70) in the culture supernatants were assayed with commercially available ELISA kits (R&D Systems, Minneapolis, MN) as directed by the manufacturer. The detection limits of these assays were 4.4 pg/ml for TNF-α, 1.2 pg/ml for IL-1β, 2.8 pg/ml for IL-6 and 5.0 pg/ml for IL-12.

    TNF bioassay.

    TNF activities in supernatant samples were measured by L929 cell cytotoxicity in the presence of actinomycin D (Ruff and Gifford, 1980; Flick and Gifford, 1984). L929 cells (3 × 104 cells/well) in 96-well culture plates were incubated with serially diluted samples in the presence of 1 μg/ml actinomycin D for 19 h. Cell viability was assessed by incubating the cells with 0.5 mg/ml MTT for another 5 h. Then the MTT-formazan produced by viable cells was dissolved in ethanol, and optical density (570–690 nm) was read (Denizot and Lang, 1986). An international standard rhTNF-α (1st International Standard for TNF-α [Human rDNA], National Institute for Biological Standards and Control, Hertfordshire, UK) was used as an assay calibrant. TNF activities in culture supernatants were expressed as I.U./ml.

    Statistics.

    All data are presented as means ± S.E. Differences in cytokine production for freshly isolated and GM-CSF-treated monocytes were analyzed by two-way analysis of variance (ANOVA). Priming effects of GM-CSF or M-CSF on TNF-α production were analyzed by one-way ANOVA followed by Dunnett’s test. The effect of anti-CD14 on TNF-α production was analyzed by paired ttest. Values less than .05 were considered statistically significant.

    Previous SectionNext Section

    Results

    Induction of TNF-α, IL-1β, IL-6 and IL-12 by ONO-4007 or LPS in monocytes freshly isolated or incubated with GM-CSF.

    First, we compared the cytokine-inducing activity of ONO-4007 (100 μg/ml) in monocytes freshly isolated or incubated for 3 days in the presence of GM-CSF (100 U/ml) with that of LPS (0.1 μg/ml). The results indicate that cytokine induction by ONO-4007 in fresh monocytes was very weak; the levels of IL-1β and IL-12 production were marginal or undetectable, and the peak levels of TNF-α (6 h) and IL-6 (24 h) production were 2.4% and 1.8% of the peak levels in monocytes stimulated with LPS, respectively (table1). In contrast to the response to ONO-4007, fresh monocytes produced significant amounts of these cytokines in response to LPS. After preincubation with GM-CSF, monocyte production of TNF-α in response to ONO-4007 increased dramatically to 12 times that in fresh monocytes (820 ± 180 vs.69 ± 11 pg/ml). However, GM-CSF-treatment did not affect IL-6 production in response to ONO-4007, and it made IL-1β and IL-12 production almost undetectable. The level of TNF-α production in response to LPS was increased 2.2-fold by GM-CSF-treatment, whereas IL-6 production and IL-12 production were not affected by the treatment, and IL-1β production was dramatically attenuated.

    View this table:
    Table 1

    Cytokines induced by ONO-4007 or LPS

    Dose-dependent effect of ONO-4007 and LPS on TNF-α production.

    Then we examined the effect of various concentrations of ONO-4007 and LPS on TNF-α production in both freshly isolated and GM-CSF-treated monocytes. In fresh monocytes, slight production of TNF-α was observed at 100 and 300 μg/ml of ONO-4007 (fig.2). In GM-CSF-treated monocytes, however, ONO-4007 induced significant amounts of TNF-α production in a dose-dependent manner (14 ± 3 pg/ml at 1 μg/ml and 1577 ± 314 pg/ml at 300 μg/ml). At 300 μg/ml of ONO-4007, the levels of TNF-α production in GM-CSF-treated monocytes were 16 times greater than those in fresh monocytes. LPS-induced TNF-α production in GM-CSF-treated monocytes was also greater than that in fresh monocytes, but it represented only a 2.0- to 2.6-fold increase.

    Figure 2
    View larger version:
    Figure 2

    Effect of various concentrations of ONO-4007 and LPS on TNF-α production. Monocytes (5 × 104 cells/ml) freshly isolated or incubated for 3 days in the presence of GM-CSF (100 U/ml) were washed and stimulated with the indicated concentrations of ONO-4007 or LPS for 6 h (n = 4). The concentrations of TNF-α in culture supernatants were measured by ELISA. Two-way ANOVA confirmed that GM-CSF-treatment increased both ONO-4007-induced and LPS-induced TNF-α production.

    Priming effects of GM-CSF and M-CSF on ONO-4007- or LPS-induced TNF-α production.

    Because both M-CSF and GM-CSF are known to be priming agents for monocyte/macrophage activation, we examined the dose-dependent effect of GM-CSF and M-CSF on monocyte TNF-α production. Monocytes were incubated for 3 days in the presence of 1 to 1000 U/ml of either GM-CSF or M-CSF and then we stimulated with ONO-4007 (300 μg/ml) or LPS (1 μg/ml). Preincubation with GM-CSF augmented monocyte TNF-α production at 10 U/ml and higher concentrations when the monocytes were stimulated with ONO-4007 and at 1 U/ml and higher concentrations when they were stimulated with LPS (fig. 3). Preincubation with M-CSF at 1000 U/ml also augmented both ONO-4007- and LPS-induced TNF-α production. Next we examined the effects of GM-CSF and M-CSF on monocyte survival. Monocytes were incubated for 3 days with GM-CSF (100 U/ml) or M-CSF (1000 U/ml), and the recovered cells were counted. The survival rate of monocytes incubated with culture medium alone was 27.5%, whereas the treatment with GM-CSF and treatment with M-CSF improved the survival to 64.9% and 53.9%, respectively (table2).

    Figure 3
    View larger version:
    Figure 3

    Priming effects of GM-CSF and M-CSF on ONO-4007- or LPS-induced TNF-α production. Monocytes (5 × 104cells/ml) incubated for 3 days with the indicated concentrations of GM-CSF or M-CSF were washed and stimulated with ONO-4007 (300 μg/ml) or LPS (1 μg/ml) for 6 h (n = 3). The concentrations of TNF-α in culture supernatants were measured by ELISA. * P < .05, ** P < .01 vs. medium alone.

    View this table:
    Table 2

    Effect of GM-CSF or M-CSF on monocyte survival

    ONO-4007-, lipid A- or LPS-induced TNF-α production in whole blood.

    To examine the effect of the possible interaction of monocytes with other leukocytes or serum factors on TNF-α production, we examined ONO-4007-, LA-15-PP (synthetic lipid A)- and LPS-induced TNF-α production in whole blood. TNF-α production in response to ONO-4007 (10, 30, 100 and 300 μg/ml) was marginal (13.2 ± 2.0 pg/ml at 300 μg/ml) (fig. 4). In contrast to ONO-4007, LA-15-PP and LPS induced significant amounts of TNF-α production at 100 pg/ml and higher concentrations; the levels of TNF-α production in response to 1 μg/ml of LA-15-PP and LPS were 15423 ± 1655 and 25014 ± 5066 pg/ml, respectively.

    Figure 4
    View larger version:
    Figure 4

    ONO-4007-, LA-15-PP- or LPS-induced TNF-α production in whole blood. Whole blood was stimulated with the indicated concentrations of the test compounds for 6 h (n = 3). The concentrations of TNF-α in supernatants were measured by ELISA.

    Requirement of FCS for ONO-4007- or LPS-induced TNF production.

    We next examined the requirement of FCS in culture medium for the induction of TNF activity in freshly isolated and GM-CSF-treated monocytes. When serum-free medium was used for monocyte activation, ONO-4007-induced TNF production by fresh monocytes was attenuated, but that by GM-CSF-treated monocytes was observed from 1 μg/ml of ONO-4007 and to a maximum at 10 μg/ml, at which concentration the levels of TNF production were 9 times greater than those stimulated in serum-containing medium (fig.5). TNF production at 30 and 100 μg/ml of ONO-4007, however, declined when GM-CSF-treated monocytes were stimulated in serum-free medium. We also observed cellular swelling and decreased number of cultured monocytes when the monocytes were stimulated with 30 and 100 μg/ml of ONO-4007 in serum-free medium, which suggests cytotoxicity of ONO-4007 in these culture conditions. The levels of LPS-induced TNF production by both fresh and GM-CSF-treated monocytes were attenuated when serum-free medium was used for monocyte activation.

    Figure 5
    View larger version:
    Figure 5

    Requirement of FCS for ONO-4007- or LPS-induced TNF production. Monocytes (5 × 104 cells/ml) freshly isolated (•) or incubated for 3 days with 100 U/ml GM-CSF (○) were washed and stimulated with ONO-4007 or LPS in 10% FCS-containing or serum-free culture medium for 6 h (n = 4). TNF activities in culture supernatants were measured by L929 cell cytotoxicity. The detection limit of the assay was 1.3 I.U./ml. Two-way ANOVA confirmed that GM-CSF treatment increased both ONO-4007- and LPS-induced TNF-α production when FCS-containing medium was used for monocyte activation and that it increased ONO-4007-induced TNF-α production when serum-free medium was used.

    Effect of anti-CD14 on ONO-4007- or LPS-induced TNF-α production.

    Finally, we examined the effect of anti-CD14 (RMO52) on TNF-α production in GM-CSF-treated monocytes. Anti-CD14 treatment completely suppressed TNF-α production in response to 0.1 ng/ml of LPS, but not in response to 30 or 300 μg/ml of ONO-4007 or to 1 μg/ml of LPS (table 3).

    View this table:
    Table 3

    Effect of anti-CD14 antibody on TNF-α production

    Correlation of TNF activity with TNF-α ELISA.

    TNF activities in monocyte supernatant samples shown in tables 1 and 3 and figures 2and 3 were assessed by L929 cell cytotoxicity as well as by ELISA. TNF activities measured by L929 cell cytotoxicity correlated well with TNF-α concentrations measured by ELISA (fig.6).

    Figure 6
    View larger version:
    Figure 6

    Correlation of TNF activity with TNF-α ELISA.

    Previous SectionNext Section

    Discussion

    This study investigated the cytokine-inducing effect of ONO-4007, a synthetic lipid A analog, on human monocytes/macrophages. ONO-4007 clearly induced TNF-α production from GM-CSF- or M-CSF-treated monocytes, but not from fresh monocytes or whole blood. The present observations are consistent with reports that pretreatment of human monocytes with GM-CSF (Cannistra et al., 1988) or M-CSF (Sampson-Johannes and Carlino, 1988; Asakura et al., 1996) enhances LPS-induced TNF-α production. Priming effects of GM-CSF or M-CSF were more pronounced when ONO-4007 was used for monocyte activation; the levels of ONO-4007-induced TNF-α production in pretreated monocytes increased to 12 to 16 times those in fresh monocytes, whereas LPS-induced production was increased only 2.0- to 2.6-fold by the pretreatment. Present findings also showed that both GM-CSF and M-CSF improved the survival of cultured monocytes, but the cell numbers did not increase during incubation. These results suggest that the effect of GM-CSF or M-CSF on TNF-α production is exerted by functional priming rather than stimulation of cell growth. Although the cytokine-inducing effect of ONO-4007 was weak in fresh monocytes, other leukocytes such as lymphocytes and neutrophils or serum factors might modulate TNF-α production in response to ONO-4007. Therefore, we examined TNF-α production in whole blood. In contrast to synthetic lipid A and LPS, ONO-4007 was less active in whole blood than in fresh monocytes; that is, the levels of ONO-4007-induced TNF-α production in whole blood were marginal, whereas the levels of LPS-induced TNF-α production were greater than those in fresh monocytes. These findings suggest that monocyte separation and adherence to a plastic plate (Ralph and Sampson-Johannes, 1990) somewhat prime monocytes for subsequent stimulation by ONO-4007 and that, therefore, ONO-4007 might not induce TNF-α production in nonstimulated blood monocytes. M-CSF is present at 100 to 200 U/ml in normal human sera (Das et al., 1981; Logan et al., 1996), but the results of this study showed that 1000 U/ml of M-CSF is required for monocyte priming, which is consistent with the inability of ONO-4007 to release TNF-α in whole blood. LPS-induced IL-1β production declined dramatically in monocytes pretreated with GM-CSF. This agrees with previous reports that IL-1β release in response to LPS was suppressed during monocyte maturation both in vivo (Herzyk et al., 1992) andin vitro (Hogquist et al., 1991).

    There were several differences between the effects of ONO-4007 and LPS on monocyte activation: 1) More than 1 μg/ml of ONO-4007 was required for monocyte TNF-α production, whereas as little as 0.1 ng/ml of LPS was sufficient for TNF-α production. 2) The effect of ONO-4007 on the induction of IL-1β, IL-6 and IL-12 production was much weaker than that of LPS. 3) ONO-4007 induced TNF-α production only in monocytes pretreated with GM-CSF or M-CSF, whereas LPS induced TNF-α production in both freshly isolated and pretreated monocytes. These differences suggest that cell activating pathways of ONO-4007 are different from those of LPS. It has been shown that LPS at very low levels (<1 ng/ml) binds to the serum protein LBP via the lipid A moiety (Schumann et al., 1990). This complex then binds to a receptor, CD14, present on the surface of monocytes/macrophages and activates these cells to produce cytokines, including TNF-α (Wrightet al., 1990; Kirkland et al., 1993). Monocyte activation by very low levels (<1 ng/ml) of LPS is inhibited by anti-CD14 treatment (Wright et al., 1990) or by elimination of LBP in the culture medium (Meszaros et al., 1995). It has also been observed that TNF-α synthesis in response to 10 ng/ml of LPS occurs in the absence of both LBP (Schumann et al.,1990) and CD14 (Heumann et al., 1992), which implies that LPS and lipid A can activate monocytes/macrophages viaLBP/CD14-independent pathway(s). The present study showed that low concentrations (1, 3 and 10 μg/ml) of ONO-4007 induced greater TNF-α production in FCS-free medium than in FCS-containing medium, whereas LPS-induced TNF-α production was attenuated by serum elimination. It was reported that bovine LBP in FCS was able to interact with human CD14 (Heumann et al., 1992). Moreover, anti-CD14 antibody treatment did not influence ONO-4007-induced TNF-α production. However, this treatment attenuated TNF-α production in response to 0.1 ng/ml, but not to 1 μg/ml, of LPS, in accordance with previous observations (Schumann et al., 1990; Heumannet al., 1992). These results suggest that ONO-4007 induces TNF-α production in monocytes via LBP/CD14-independent pathways, whereas LPS uses both LBP/CD14-dependent and -independent pathways. It has been observed that ONO-4007 binds to human serum albumin and that bovine serum albumin added to culture attenuates the cytotoxic effect of ONO-4007 on endothelial cells (N. Matsumoto and A. Akimoto, unpublished observation). This indicates that serum albumin binds to ONO-4007 and inhibits the activity of ONO-4007. Elevated TNF-α production at 1, 3 and 10 μg/ml and cytotoxicity at 30 and 100 μg/ml of ONO-4007 in FCS-free medium could be due to the absence of serum albumin in the culture medium.

    GM-CSF is secreted by various cell types (activated T cells, activated macrophages, endothelial cells and fibroblasts) in response to antigenic or inflammatory stimulus (Dipersio, 1990; Monroy et al., 1990). M-CSF is constitutively secreted by fibroblasts, endothelial cells and epithelial cells (Ralph and Sampson-Johannes, 1990). Human monocytes produce M-CSF for their own use in response to inflammatory stimulus (Ralph and Sampson-Johannes, 1990). Moreover, tumor cells often produce M-CSF at high levels, as has been demonstrated in ovarian (Bauknecht et al., 1994), endometrial (Ramakrishnan et al., 1989), pulmonary (Horiguchi et al., 1988), pancreatic (Ralph et al., 1986) and breast cancer (Kacinski et al., 1991).Tang et al. (1990) reported that M-CSF expression of tumor cells strongly correlated with the infiltration of macrophages and lymphocytes in human breast carcinoma. These reports suggest that tumor-infiltrating macrophages in cancer patients would be primed for ONO-4007 stimulation if some immune responses were generated in their tumor tissues or if the cancer cells themselves secreted M-CSF.

    In the present study, we used as a reference agent LPS fromSalmonella abortus equi, which has been used in clinical phase I and II trials in cancer patients (Engelhardt et al.,1991 and 1995). In these studies, tumor response was observed in several patients with colorectal carcinoma; however, side effects such as fever, chill, hepatic toxicity and hypotension were also observed. Serum TNF-α levels in patients treated with a therapeutic dose (4 ng/kg b.wt.) of LPS were elevated to 3 to 10 ng/ml. The toxic side effects of LPS are thought to be exerted via systemic activation of monocytes/macrophages, because LPS strongly activates monocytes to release proinflammatory cytokines, including TNF-α, in both fresh and primed monocytes. Because ONO-4007 activates human monocytes/macrophages to release TNF-α only in a primed state, it would activate only tumor-infiltrating primed macrophages in cancer patients, not blood monocytes or resting tissue macrophages. Therefore, ONO-4007 might show potent antitumor activity with relatively low toxicity compared with LPS in cancer patients.

    In conclusion, this study shows that ONO-4007 activates human monocytes/macrophages to release TNF-α only in a primed state and suggests that ONO-4007 would activate these cells viadifferent pathways than would LPS.

    Previous SectionNext Section

    Acknowledgments

    We are grateful to Mrs. Yuki Mori for her technical assistance.

    Previous SectionNext Section

    Footnotes

    • Send reprint requests to: Norihito Matsumoto, 50-10 Yamagishi, Mikuni-cho, Sakai-gun, Fukui, 913, Japan.

    • Abbreviations:
      ELISA
      enzyme-linked immunosorbent assay
      FCS
      fetal calf serum
      GM-CSF
      granulocyte-macrophage colony-stimulating factor
      IL
      interleukin
      LBP
      LPS-binding protein
      LPS
      lipopolysaccharide
      M-CSF
      macrophage colony-stimulating factor
      MTT
      3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
      TNF
      tumor necrosis factor
      • Received July 8, 1997.
      • Accepted September 5, 1997.
    Previous Section
     

    References

    1. ↵
      1. Asakura A,
      2. Hanamura T,
      3. Umemura A,
      4. Yada K,
      5. Yamauchi T,
      6. Tanabe T
      (1996) Effects of macrophage colony-stimulating factor (M-CSF) on lipopolysaccharide (LPS)-induced mediator production from monocytes in vitro. Immunobiology 195:300–313.
      Medline
    2. ↵
      1. Bauknecht T,
      2. Kiechle-Schwarz M,
      3. duBois A,
      4. Wolfle J,
      5. Kacinski B
      (1994) Expression of transcripts for CSF-1 and for the “macrophage” and “epithelial” isoforms of the CSF-1R transcripts in human ovarian carcinomas. Cancer Detect Prev 18:231–239.
      Medline
    3. ↵
      1. Cannistra SA,
      2. Vellenga E,
      3. Groshek P,
      4. Rambaldi A,
      5. Griffin JD
      (1988) Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 71:672–676.
      Abstract/FREE Full Text
    4. ↵
      1. Das SK,
      2. Stanley ER,
      3. Guibert LJ,
      4. Forman LW
      (1981) Human colony-stimulating factor (CSF-1) radioimmunoassay: Resolution of three subclasses of human colony-stimulating factors. Blood 58:630–641.
      FREE Full Text
    5. ↵
      1. Delude RL,
      2. Savedra RJ,
      3. Zharo H,
      4. Thieringer R,
      5. Yamamoto S,
      6. Fenton MJ,
      7. Golenbock DT
      (1995) CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Proc Natl Acad Sci USA 92:9288–9292.
      Abstract/FREE Full Text
    6. ↵
      1. Denizot F,
      2. Lang R
      (1986) Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth 89:271–277.
      CrossRefMedlineWeb of Science
    7. ↵
      1. Dimri R,
      2. Nissimov L,
      3. Keisari Y
      (1994) Effect of human recombinant granulocyte-macrophage colony-stimulating factor and IL-3 on the expression of surface markers of human monocyte-derived macrophages in long-term cultures. Lymphokine Cytokine Res 13:239–245.
      Medline
    8. ↵
      1. Dipersio JF
      (1990) Colony-stimulating factors: Enhancement of effector cell function. Cancer Surv 9:81–113.
      MedlineWeb of Science
    9. ↵
      1. Engelhardt R,
      2. Mackensen A,
      3. Galanos C
      (1991) Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 51:2524–2530.
      Abstract/FREE Full Text
    10. ↵
      1. Engelhardt R,
      2. Otto F,
      3. Mackensen A,
      4. Mertelsmann R,
      5. Galanos C
      (1995) Endotoxin (Salmonella abortus equi) in cancer patients: Clinical and immunological findings. Prog Clin Biol Res 392:253–261.
      Medline
    11. ↵
      1. Erickson-Miller CL,
      2. Brennan JK,
      3. Abboud CN
      (1990) Examination of survival, proliferation and cell surface antigen expression of human monocytes exposed to macrophage colony-stimulating factor (M-CSF). Int J Cell Cloning 8:346–356.
      Medline
    12. ↵
      1. Flick DA,
      2. Gifford GE
      (1984) Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Meth 68:167–175.
      CrossRefMedlineWeb of Science
    13. ↵
      1. Geissler K,
      2. Harrington M,
      3. Srivastava C,
      4. Leemhuis T,
      5. Tricot G,
      6. Broxmeyer HE
      (1989) Effects of recombinant human colony stimulating factors (CSF) (granulocyte-macrophage CSF, granulocyte CSF, and CSF-1) on human monocyte/macrophage differentiation. J Immunol 143:140–146.
      Abstract
    14. ↵
      1. Golenbock DT,
      2. Hampton RY,
      3. Qureshi N,
      4. Takayama K,
      5. Raetz CRH
      (1991) Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 266:19490–19498.
      Abstract/FREE Full Text
    15. ↵
      1. Hashimoto S,
      2. Yamada M,
      3. Motoyoshi K,
      4. Akagawa KS
      (1997) Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10. Blood 89:315–321.
      Abstract/FREE Full Text
    16. ↵
      1. Herzyk DJ,
      2. Allen JN,
      3. Marsh CB,
      4. Wewers MD
      (1992) Macrophage and monocyte IL-1β regulation differs at multiple sites: Messenger RNA expression, translation, and post-translational processing. J Immunol 149:3052–3058.
      Abstract
    17. ↵
      1. Heumann D,
      2. Gallay P,
      3. Barras C,
      4. Zaech P,
      5. Ulevitch RJ,
      6. Tobias PS,
      7. Glauser M,
      8. Baumgartner JD
      (1992) Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol 148:3505–3512.
      Abstract
    18. ↵
      1. Hogquist KA,
      2. Unanue ER,
      3. Chaplin DD
      (1991) Release of IL-1 from mononuclear phagocytes. J Immunol 147:2181–2186.
      Abstract
    19. ↵
      1. Homma JY,
      2. Matsuura M,
      3. Kanegasaki S,
      4. Kawakubo Y,
      5. Kojima Y,
      6. Shibukawa N,
      7. Kumazawa Y,
      8. Yamamoto A,
      9. Tanamoto K,
      10. Yasuda T,
      11. Imoto M,
      12. Yoshimura H,
      13. Kusumoto S,
      14. Shiba T
      (1985) Structural requirements of lipid A responsible for the functions: A study with chemically synthesized lipid A and its analogues. J Biochem 98:395–406.
      Abstract/FREE Full Text
    20. ↵
      1. Horiguchi J,
      2. Sherman ML,
      3. Sampson-Johannes A,
      4. Weber BL,
      5. Kufe DW
      (1988) CSF-1 and C-FMS gene expression in human carcinoma cell lines. Biochem Biophys Res Commun 157:395–401.
      CrossRefMedlineWeb of Science
    21. ↵
      1. Kacinski BM,
      2. Scata KA,
      3. Carter D,
      4. Yee LD,
      5. Sapi E,
      6. King BL,
      7. Chambers SK,
      8. Jones MA,
      9. Pirro MH,
      10. Stanley ER,
      11. Rohrschneider LR
      (1991) FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6:941–952.
      MedlineWeb of Science
    22. ↵
      1. Kanegasaki S,
      2. Tanamoto K,
      3. Yasuda T,
      4. Homma JY,
      5. Matsuura M,
      6. Nakatsuka M,
      7. Kumazawa Y,
      8. Yamamoto A,
      9. Shiba T,
      10. Kusumoto S,
      11. Imoto M,
      12. Yoshimura H,
      13. Shimamoto T
      (1986) Structure-activity relationship of lipid A: Comparison of biological activities of natural and synthetic lipid A’s with different fatty acid compositions. J Biochem 99:1203–1210.
      Abstract/FREE Full Text
    23. ↵
      1. Kirkland TN,
      2. Finley F,
      3. Leturcq D,
      4. Moriarty A,
      5. Lee JD,
      6. Ulevitch RJ,
      7. Tobias PS
      (1993) Analysis of lipopolysaccharide binding by CD14. J Biol Chem 268:24818–24823.
      Abstract/FREE Full Text
    24. ↵
      1. Kotani S,
      2. Takada H,
      3. Tsujimoto M,
      4. Ogawa T,
      5. Mori Y,
      6. Sakuta M,
      7. Kawasaki A,
      8. Inage M,
      9. Kusumoto S,
      10. Shiba T,
      11. Kasai N
      (1983) Immunobiological activities of synthetic lipid A analogs and related compounds as compared with those of bacterial lipopolysaccharide, Re-glycolipid, lipid A, and muramyl dipeptide. Infect Immun 41:758–773.
      Abstract/FREE Full Text
    25. ↵
      1. Kuramitsu Y,
      2. Nishibe M,
      3. Ohiro Y,
      4. Matsushita K,
      5. Yuan L,
      6. Obara M,
      7. Kobayashi M,
      8. Hosokawa M
      (1997) A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor-α in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells. Anti-Cancer Drugs 8:500–508.
      Medline
    26. ↵
      1. Logan TF,
      2. Gooding W,
      3. Kirkwood JM,
      4. Shadduck RK
      (1996) Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients. Exp Hematol 24:49–53.
      MedlineWeb of Science
    27. ↵
      1. Maeda H,
      2. Saiki I,
      3. Yamamoto N,
      4. Takahashi T,
      5. Sekiguchi S,
      6. Kiso M,
      7. Hasegawa A,
      8. Azuma I
      (1990) Activation by synthetic lipid A subunit analogues (GLA compounds) of tumorcidal properties in human blood monocytes. Vaccine 8:237–242.
      CrossRefMedline
    28. ↵
      1. Matsuura M,
      2. Shimada S,
      3. Kiso M,
      4. Hasegawa A,
      5. Nakano M
      (1995) Expression of endotoxic activities by synthetic monosaccharide lipid A analogs with alkyl-branched acyl substituents. Infect Immun 63:1446–1451.
      Abstract
    29. ↵
      1. Meszaros K,
      2. Aberle S,
      3. White M,
      4. Parent JB
      (1995) Immunoreactivity and bioactivity of lipopolysaccharide-binding protein in normal and heat-inactivated sera. Infect Immun 63:363–365.
      Abstract
    30. ↵
      1. Monroy RL,
      2. Davis TA,
      3. Macvittie TJ
      (1990) Granulocyte-macrophage colony-stimulating factor: More than a hemopoietin. Clin Immunol Immunopathol 54:333–346.
      CrossRefMedlineWeb of Science
    31. ↵
      1. Nakatsuka M,
      2. Kumazawa Y,
      3. Matsuura M,
      4. Homma JY,
      5. Kiso M,
      6. Hasegawa A
      (1989) Enhancement of nonspecific resistance to bacterial infections and tumor regressions by treatment with synthetic lipid A-subunit analogs. Critical role of N- and 3-O-linked acyl groups in 4-O-phosphono-d-glucosamine derivatives. Int J Immunopharmacol 11:349–358.
      CrossRefMedlineWeb of Science
    32. ↵
      1. Ralph P,
      2. Warren MK,
      3. Lee MT,
      4. Csejtey J,
      5. Weaver JF,
      6. Broxmeyer HE,
      7. Williams DE,
      8. Stanley ER,
      9. Kawasaki ES
      (1986) Inducible production of human macrophage growth factor, CSF-1. Blood 68:633–639.
      Abstract/FREE Full Text
    33. ↵
      1. Ralph P,
      2. Sampson-Johannes A
      (1990) Macrophage growth and stimulating factor, M-CSF. Prog Clin Biol Res 338:43–63.
      Medline
    34. ↵
      1. Ramakrishnan S,
      2. Xu FJ,
      3. Brandt SJ,
      4. Niedel JE,
      5. Bast RCJ,
      6. Brown EL
      (1989) Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83:921–926.
    35. ↵
      1. Ruff MR,
      2. Gifford GE
      (1980) Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol 125:1671–1677.
      Abstract
    36. ↵
      1. Sampson-Johannes A,
      2. Carlino JA
      (1988) Enhancement of human monocyte tumorcidal activity by recombinant M-CSF. J Immunol 141:3680–3686.
      Abstract
    37. ↵
      1. Schumann RR,
      2. Leong SR,
      3. Flaggs GW,
      4. Gray PW,
      5. Wright SD,
      6. Mathison JC,
      7. Tobias PS,
      8. Ulevitch RJ
      (1990) Structure and function of lipopolysaccharide binding protein. Science (Wash DC) 249:1429–1431.
      Abstract/FREE Full Text
    38. ↵
      1. Schutze E,
      2. Hildebrandt J,
      3. Liehl E,
      4. Lam C
      (1994) Protection of mice from mortality caused by living and heat-killed bacteria by SDZ MRL 953. Circ Shock 42:121–127.
      Medline
    39. ↵
      1. Takada H,
      2. Kotani S,
      3. Tsujimoto M,
      4. Ogawa T,
      5. Takahashi I,
      6. Harada K,
      7. Katsukawa C,
      8. Tanaka S,
      9. Shiba T,
      10. Kusumoto S,
      11. Imoto M,
      12. Yoshimura H,
      13. Yamamoto M,
      14. Shimamoto T
      (1985) Immunopharmacological activities of a synthetic counterpart of a biosynthetic lipid A precursor molecule and its analogs. Infect Immun 48:219–227.
      Abstract/FREE Full Text
    40. ↵
      1. Tang RP,
      2. Kacinski B,
      3. Validire P,
      4. Beuvon F,
      5. Sastre X,
      6. Benoit P,
      7. dela-Rochefordiere A,
      8. Mosseri V,
      9. Pouillart P,
      10. Scholl S
      (1990) Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: A role for hematopoietic growth factor release by tumor cells? J Cell Biochem 44:189–198.
      CrossRefMedline
    41. ↵
      1. Ulrich JT,
      2. Myers KR
      (1995) Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 6:495–524.
      Medline
    42. ↵
      1. Wright SD,
      2. Ramos RA,
      3. Tobias PS,
      4. Ulevitch RJ,
      5. Mathison JC
      (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (Wash DC) 249:1431–1433.
      Abstract/FREE Full Text
    43. ↵
      1. Yang D,
      2. Satoh M,
      3. Ueda H,
      4. Tsukagoshi S,
      5. Yamazaki M
      (1994) Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 38:287–293.
      Medline
    « Previous | Next Article »Table of Contents

    This Article

    1. JPET January 1, 1998 vol. 284 no. 1 189-195
    1. AbstractFree
    2. » Full Text
    3. Full Text (PDF)

    Classifications

    Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 2009, 331 (2)
    1. Current Issue
    1. Alert me to new issues of JPET